Hyponatremia, Heart Failure, and the Role of Tolvaptan

References

• . Palmer B F, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003;37(11):1694–1702
   PubMed Web of Science ®Google Scholar
• . Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064–2072
   PubMed Web of Science ®Google Scholar
• . Waikar SS, Mount DB, Curham GC. Mortality and hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009; 122(9):857–865
   PubMed Web of Science ®Google Scholar
• . Shorr AF, Tabak Y P, Johannes RS, . Burden of sodium abnormalities in patients hospitalized for heart failure. Congest Heart Fail. 2011;17(1):1–7
   PubMedGoogle Scholar
• . Gheorghiade M, Abraham WT, Albert NM, . Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28(8):980–988
   PubMed Web of Science ®Google Scholar
• . Gheorghiade M, Rossi JS, Cotts W, . Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007;167(18):1998–2005
   PubMed Web of Science ®Google Scholar
• . Barsheshet A, Shotan A, Cohen E, ; HFSIS Steering Committee and Investigators. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail. 2010;12(8): 833–840
   PubMed Web of Science ®Google Scholar
• . Goldberg A, Hammerman H, Petcherski S, . Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med. 2006;166(7):781–786
   PubMedGoogle Scholar
• . Singla I, Zahid M, Good CB, . Effect of hyponatremia (<135 mEq/L) on outcome in patients with non—ST-elevation acute coronary syndrome. Am J Cardiol. 2007;100(3):406–408
   PubMed Web of Science ®Google Scholar
• . Chin MH, Goldman L. Correlates of major complications or death in patients admitted to hospital with congestive heart failure. Arch Intern Med. 1996;156(16):1814–1820
   PubMedGoogle Scholar
• . Kearney MT, Fox KAA, Lee AJ, . Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40(10):1801–1808
   PubMed Web of Science ®Google Scholar
• . Lee DS, Austin PC, Rouleau JL, . Predicting mortality among patients hospitalized for heart failure. Derivation and validation of a clinical model. JAMA. 2003;290(19):2581–2587
   PubMed Web of Science ®Google Scholar
• . Chen MC, Chang H W, Cheng CI, Chen YH, Chai HT. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology. 2003;100(3):136–142
   PubMed Web of Science ®Google Scholar
• . O'Connor CM, Abraham WT, Albert NM, . Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156(4):662–673
   PubMed Web of Science ®Google Scholar
• . Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342(21):1581–1589
   PubMed Web of Science ®Google Scholar
• . Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005;25(3):240–249
   PubMed Web of Science ®Google Scholar
• . Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11A):S1–S21
   PubMed Web of Science ®Google Scholar
• . Verbalis JG. AV P receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006;73( suppl 3): S24–S33
   PubMedGoogle Scholar
• . LeJemtel TH, Serrano C. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. Int J Cardiol. 2007;120(1):1–9
   PubMed Web of Science ®Google Scholar
• . Goldsmith SR. Treating hyponatremia in heart failure. Curr Cardiol Rep. 2006;8:204–210
   PubMedGoogle Scholar
• . Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42(5):790–806
   PubMed Web of Science ®Google Scholar
• . Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–153
   PubMed Web of Science ®Google Scholar
• . Peterson PN, Rumsfeld JS, Liang L, . A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With the Guidelines Program. Circ Cardiovasc Qual Outcomes. 2010;3(1):25–32
   PubMed Web of Science ®Google Scholar
• . O'Connor CM, Hasselblad V, Mehta RH, . Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010;55(9):872–878
   PubMed Web of Science ®Google Scholar
• . Levy WC, Mozaffarian D, Linker DT, . The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424–1433
   PubMed Web of Science ®Google Scholar
• . Forfa PR, Mathai SC, Fisher MR, . Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177(12):1364–1369
   PubMed Web of Science ®Google Scholar
• . Dimopoulos K, Diller G—P, Petraco R, . Hyponatremia: a strong predictor of mortality in adults with congenital heart disease. Eur Heart J. 2010;31(5):595–601
   PubMed Web of Science ®Google Scholar
• . Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294–302
   PubMedGoogle Scholar
• . Hunt SA, Abraham WT, Chin MH, ; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2005;112:e154–e235
   PubMedGoogle Scholar
• . Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37(3):149–155
   PubMed Web of Science ®Google Scholar
• . Sterns RH, Silver SM. Brain volume regulation in response to hypoosmolality and its correction. Am J Med. 2006;119( suppl 1): S12–S16
   Web of Science ®Google Scholar
• . Heart Failure Society of America; Lindenfeld J, Albert NM, Boehmer J P, et al.HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–e194
   PubMed Web of Science ®Google Scholar
• . Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: evaluation and management. Hosp Pract. 2010;38(1):89–96
   PubMedGoogle Scholar
• . Schrier RW, Bansal S. Diagnosis and management of hyponatremia in acute illness. Curr Opin Crit Care. 2008;14(6):627–634
   PubMed Web of Science ®Google Scholar
• . Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29(3):282–299
   PubMed Web of Science ®Google Scholar
• . Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med. 2010;77(10): 715–726
   PubMed Web of Science ®Google Scholar
• . Sterns RH, Cappuccio JD, Silver SM, Cohen E P. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4(8):1522–1530
   PubMed Web of Science ®Google Scholar
• . Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry. 2004;75( suppl 3):iii22–iii28
   PubMed Web of Science ®Google Scholar
• . Ghali JK, Tam S W. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail. 2010;16(5):419–431
   PubMed Web of Science ®Google Scholar
• . Licata G, Pasquale PD, Parrinello G, . Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145(3):459–466
   PubMed Web of Science ®Google Scholar
• . Paterna S, Di Pasquale P, Parrinello G, . Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail. 2000;2(3):305–313
   PubMed Web of Science ®Google Scholar
• . Hunt SA, Abraham WT, Chin MH, . 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–e479
   PubMedGoogle Scholar
• . Vaprisol (conivaptan hydrochloride) injection, for intravenous use [package insert]. Deerfield, IL: Astellas Pharma US, Inc; February 2011
   Google Scholar
• . Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–457
   PubMed Web of Science ®Google Scholar
• . Ghali JK, Koren MJ, Taylor JR, . Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–2152
   PubMed Web of Science ®Google Scholar
• . Annane D, Decaux G, Smith N; Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337(1):28–36
   PubMed Web of Science ®Google Scholar
• . Yamamura Y, Nakamura S, Itoh S, . OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral doses in rats. J Pharmacol Exp Ther. 1998;287(3):860–867
   PubMed Web of Science ®Google Scholar
• . Costello—Boerrigter LC, Smith WB, Boerrigter G, . Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290(2):F273–F278
   PubMed Web of Science ®Google Scholar
• . Gheorghiade M, Gattis WA, O'Connor CM, . Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963–1971
   PubMed Web of Science ®Google Scholar
• . Udelson JE, Bilsker M, Hauptman PJ, . A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17(12):973–981
   PubMed Web of Science ®Google Scholar
• . Schrier RW, Gross P, Gheorghiade M, ; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–2112
   PubMed Web of Science ®Google Scholar
• . Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec F. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011;164(5):725–732
   PubMed Web of Science ®Google Scholar
• . Samsca™ (tolvaptan) tablets for oral use [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc; May 2009
   Google Scholar
• . Gheorghiade M, Gottlieb SS, Udelson JE, . Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97(7):1064–1067
   PubMed Web of Science ®Google Scholar
• . Gheorghiade M, Konstam MA, Burnett JC Jr, . Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. The EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–1343
   PubMed Web of Science ®Google Scholar
• . Konstam MA, Gheorghiade M, Burnett JC Jr, ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331
   PubMed Web of Science ®Google Scholar
• . Pang PS, Konstam MA, Krasa HB, ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30(18):2233–2240
   PubMed Web of Science ®Google Scholar
• . Udelson JE, Orlandi C, Ouyang J, . Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J Am Coll Cardiol. 2008;52(19):1540–1545
   PubMed Web of Science ®Google Scholar
• . Cyr PL, Slawsky KA, Olchanski N, . Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health-Syst Pharm. 2011;68(4): 328–333
   PubMed Web of Science ®Google Scholar
• . Tribouilloy C, Buiciuc O, Rusinaru D, . Long-term outcome after a first episode of heart failure. A prospective 7-year study. Int J Cardiol. 2010;140(3):309–314
   PubMed Web of Science ®Google Scholar
• . Bettari L, Fiuzat M, Shaw LK, . Hyponatremia and long-term outcomes in heart failure. Poster presented at: 60th Annual Scientific Session of the American College of Cardiology; April 2–5, 2011; New Orleans, LA
   Google Scholar